Anabolic steroids in sport: Biochemical, clinical and analytical perspectives

Annals of Clinical Biochemistry

Volumn 40, Issue 4, 2003, Pages 321-356

  Kicman, Andrew T ^a   Gower, D B ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; ANDORON; ANDROGEN; BOLASTERONE; BOLDENONE; BOLDENONE UNDECENOATE; CALUSTERONE; CLOSTEBOL; CLOSTEBOL ACETATE; CRESTABOLIC; DROSTANOLONE; DROSTANOLONE PROPIONATE; FLUOXYMESTERONE; FRAZALON; FURAZABOL; LONAVAR; MESTANOLONE; MESTEROLONE; METANDIENONE; METENOLONE; METENOLONE ACETATE; METHANDRIOL; METHYLTESTOSTERONE; NANDROLONE DECANOATE; NORETHANDROLONE; OXANDROLONE; OXYMETHOLONE; RIEDEMIL; STANOZOLOL; TESTOSTERONE DERIVATIVE; TRENBOLONE; TURANIBOL;

ACNE CYSTICA; AGGRESSION; AMENORRHEA; CLINICAL FEATURE; DOPING; DRUG EFFECT; DRUG FATALITY; DRUG METABOLISM; DRUG STRUCTURE; GYNECOMASTIA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERTENSION; INFERTILITY; MENSTRUAL IRREGULARITY; MUSCLE STRENGTH; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SIDE EFFECT; SPORTS MEDICINE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TESTIS ATROPHY; VIRILIZATION;

ANABOLIC AGENTS; ANDROGENS; ANDROSTANES; CARDIOVASCULAR SYSTEM; CHORIONIC GONADOTROPIN; DOPING IN SPORTS; EVIDENCE-BASED MEDICINE; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LIVER; MALE; MUSCLE, SKELETAL; PHYSICAL ENDURANCE; PROSTATE; SPECIMEN HANDLING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0038342935     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/000456303766476977     Document Type: Review

References (222)

1. Ruckzika L, Wettstein A, Kaegi H. Sexualhormone VIII Darstellung von Testosterone unter Anwendung gemischter Ester. Helv Chim Acta 1935; 18: 1478
2. Todd T. Anabolic steroids: the gremlins of sport. J Sport History 1987; 14: 87-107
3. Hershberger LG, Shipley EG, Meyer RK. Myotrophic activity of 19-nortestosterone and other steroids determined by modified levator ani muscle method. Proc Soc Exp Biol Med 1953; 83: 175-80
4. Kruskemper HL. Anabolic Steroids. New York: Academic Press, 1968: 236
5. Budavari S, ed. The Merck Index. Whitehouse Station, NJ: Merck, 1996
6. Beckett AH. Use and abuse of drugs in sport. J Biosoc Sci Suppl 1981; 7: 163-78
7. Abraham GE. Solid-phase radioimmunoassay of estradiol-17β. J Clin Endocrinol Metab 1969; 29: 866-70
8. Brooks RV, Firth RG, Sumner NA. Detection of anabolic steroids by radioimmunoassay. Br J Sports Med 1975; 9: 89-92
9. Ward RJ, Shackleton CH, Lawson AM. Gas chromatographic-mass spectrometric methods for the detection and identification of anabolic steroid drugs. Br J Sports Med 1975; 9: 93-7
10. Brooks RV, Jeremiah G, Webb WA, Wheeler M. Detection of anabolic steroid administration to athletes. J Steroid Biochem 1979; 11: 913-7
11. Hampl R, Starka L. Practical aspects of screening of anabolic steroids in doping control with particular accent to nortestosterone radioimmunoassay using mixed antisera. J Steroid Biochem 1979; 11: 933-6
12. Kicman AT, Brooks RV. Radioimmunoassay for nandrolone metabolites. J Pharm Biomed Anal 1988; 6: 473-83
13. Catlin DH, Kammerer RC, Hatton CK, Sekera MH, Merdink JL. Analytical chemistry at the Games of the XXIIIrd Olympiad in Los Angeles, 1984. Clin Chem 1987; 33: 319-27
14. Swiss Pharmaceutical Society. Index Nominum: International Drug Directory. Stuttgart: Medpharm Scientific Publishers, 1995
15. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994; 78: 1360-7
16. Di Pasquale MG. Dehydroepiandrosterone (DHEA). Beyond Anabolic Steroids. Ontario: MGD Press, 1990: 63
17. Olympic Movement Anti-Doping Code. Access via http:// www.olympic.org (under 'Ask a question' type 'Anti-Doping Code'); date last accessed 8 October 2002
18. Catlin DH, Leder BZ, Ahrens B, et al. Trace contamination of over-the-counter androstenedione and positive urine test results for a nandrolone metabolite. JAMA 2000; 284: 2618-21
19. Tomoda H. Effect of oxymetholone on left ventricular dimensions in heart failure secondary to idiopathic dilated cardiomyopathy or to mitral or aortic regurgitation. Am J Cardiol 1999; 83: 123-5, A9
20. Bhasin S, Woodhouse L, Storer TW. Proof of the effect of testosterone on skeletal muscle. J Endocrinol 2001; 170: 27-38
21. Bogin V, Shaw-Stiffel T. Androgenic anabolic steroids and other therapies for HIV-related wasting. J Clin Ligand Assay 1999; 22: 268-78
22. Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther 2001; 23: 1355-90
23. Hengge UR, Baumann M, Maleba R, Brockmeyer NH, Goos M. Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection. Br J Nutr 1996; 75: 129-38
24. Ryan AJ. Athletics. In: Kochakian CD, ed. Anabolic-Androgenic Steroids, Vol. 43. Berlin: Springer-Verlag, 1976: 515-34 (see also Addendum, p. 723)
25. Haupt HA, Rovere GD. Anabolic steroids: a review of the literature. Am J Sports Med 1984; 12: 469-84
26. Alen M, Hakkinen K. Androgenic steroid effects on serum hormones and on maximal force development in strength athletes. J Sports Med Phys Fitness 1987; 27: 38-46
27. Strauss RH, Yesalis CE. Anabolic steroids in the athlete. Annu Rev Med 1991; 42: 449-57
28. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335: 1-7
29. Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001; 281: E1172-81
30. Welle S, Jozefowicz R, Statt M. Failure of dehydroepiandrosterone to influence energy and protein metabolism in humans. J Clin Endocrinol Metab 1990; 71: 1259-64
31. Nestler JE, Barlascini CO, Clore JN, Blackard WG. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab 1988; 66: 57-61
32. King DS, Sharp RL, Vukovich MD, et al. Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men: a randomized controlled trial. JAMA 1999; 281: 2020-8
33. Leder BZ, Longcope C, Catlin DH, Ahrens B, Schoenfeld DA, Finkelstein JS. Oral androstenedione administration and serum testosterone concentrations in young men. JAMA 2000; 283: 779-82
34. Brown GA, Vukovich MD, Sharp RL, Reifenrath TA, Parsons KA, King DS. Effect of oral DHEA on serum testosterone and adaptations to resistance training in young men. J Appl Physiol 1999; 87: 2274-83
35. Uralets VP, Gillette PA. Over-the-counter anabolic steroids 4-androsten-3,17-dione; 4-androsten-3β,17β-diol; and 19-nor-4-androsten-3,17-dione: excretion studies in men. J Anal Toxicol 1999; 23: 357-66
36. Uralets VP, Gillette PA. Over-the-counter Δ5 anabolic steroids 5-androsen-3,17-dione; 5-androsten-3β,17β-diol; dehydroepiandrosterone; and 19-nor-5-androsten-3,17-dione: excretion studies in men. J Anal Toxicol 2000; 24: 188-93
37. Horton R, Tait JF. Androstenedione production and interconversion rates measured in peripheral blood and studies on the possible site of its conversion to testosterone. J Clin Invest 1966; 45: 301-13
38. Bardin CW, Lipsett MB. Testosterone and androstenedione blood production rates in normal women and women with idiopathic hirsutism or polycystic ovaries. J Clin Invest 1967; 46: 891-902
39. Mahesh VB, Greenblatt GR. The in vivo conversion of dehydroepiandrosterone and androstenedione to testosterone in the human. Acta Endocrinol 1962; 41: 400-6
40. Kicman AT, Bassindale T, Cowan DA, Dale S, Hutt AJ, Leeds AR. The effect of androstenedione ingestion on plasma testosterone in young women; a dietary supplement with potential health risks. Clin Chem 2003; 49: 167-9
41. Dahlberg E, Snochowski M, Gustafsson JA. Regulation of the androgen and glucocorticoid receptors in rat and mouse skeletal muscle cytosol. Endocrinology 1981; 108: 1431-40
42. Hervey GR. What are the effects of anabolic steroids? In: Davies B, Thomas G, eds. Science and Sporting Performance. Oxford: Clarendon Press, 1982: 120-36
43. Hickson RC, Czerwinski SM, Falduto MT, Young AP. Glucocorticoid antagonism by exercise and androgenic-anabolic steroids. Med Sci Sports Exerc 1990; 22: 331-40
44. Sharpe PM, Buttery PJ, Haynes NB. The effect of manipulating growth in sheep by diet or anabolic agents on plasma cortisol and muscle glucocorticoid receptors. Br J Nutr 1986; 56: 289-304
45. Wu FC. Endocrine aspects of anabolic steroids. Clin Chem 1997; 43: 1289-92
46. Brooks RV. Some aspects of the action of anabolic steroids on athletes. In: Landry F, Oraban WAR, eds. Physical Activity and Human Well-Being. Quebec: Symposia Specialists, 1978: 219-29
47. Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocr Rev 1987; 8: 1-28
48. Di Pasquale MG. Anabolic Steroid Side-Effects: Facts, Fiction and Treatment. Ontario: MGD Press, 1990: 63
49. Graham S, Kennedy M. Recent developments in the toxicology of anabolic steroids. Drug Saf 1990; 5: 458-76
50. Landry GL, Primos WA Jr. Anabolic steroid abuse. Adv Pediatr 1990; 37: 185-205
51. Franke WW, Berendonk B. Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government. Clin Chem 1997; 43: 1262-79
52. Cicardi M, Bergamaschini L, Tucci A, et al. Morphologic evaluation of the liver in hereditary angioedema patients on long-term treatment with androgen derivatives. J Allergy Clin Immunol 1983; 72: 294-8
53. Dickerman RD, Pertusi RM, Zachariah NY, Dufour DR, McConathy WJ. Anabolic steroid-induced hepatotoxicity: is it overstated? Clin J Sport Med 1999; 9: 34-9
54. Pope HG Jr, Katz DL. Homicide and near-homicide by anabolic steroid users. J Clin Psychiatry 1990; 51: 28-31
55. Pope HG Jr, Katz DL. Affective and psychotic symptoms associated with anabolic steroid use. Am J Psychiatry 1988; 145: 487-90
56. Choi PY, Pope HG Jr. Violence toward women and illicit androgenic-anabolic steroid use. Ann Clin Psychiatry 1994; 6: 21-5
57. Yesalis CE, Vicary JR, Buckley WE, Streit AL, Katz DL, Wright JE. Indications of psychological dependence among anabolic-androgenic steroid abusers. NIDA Res Monogr 1990; 102: 196-214
58. Hurley BF, Seals DR, Ehsani AA, et al. Effects of high-intensity strength training on cardiovascular function. Med Sci Sports Exerc 1984; 16: 483-8
59. Cohen JC, Faber WM, Benade AJS, Noakes TD. Altered serum-lipoprotein profiles in male and female power lifters ingesting anabolic-steroids. Physician Sportsmed 1986; 14: 131-6
60. Kuipers H, Wijnen JA, Hartgens F, Willems SM. Influence of anabolic steroids on body composition, blood pressure, lipid profile and liver functions in body-builders. Int J Sports Med 1991; 12: 413-8
61. Sader MA, Griffiths KA, McCredie RJ, Handelsman DJ, Celermajer DS. Androgenic-anabolic steroids and arterial structure and function in male body-builders. J Am Coll Cardiol 2001; 37: 224-30
62. Sullivan ML, Martinez CM, Gallagher EJ. Atrial fibrillation and anabolic steroids. J Emerg Med 1999; 17: 851-7
63. Parssinen M, Kujala U, Vartiainen E, Sarna S, Seppala T. Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int J Sports Med 2000; 21: 225-7
64. Magnavita N, Teofili L, Leone G. Hodgkin's lymphoma in a cyclist treated with growth hormone. Am J Hematol 1996; 52: 65-6
65. Nieminen MS, Ramo MP, Viitasalo M, et al. Serious cardiovascular side-effects of large doses of anabolic steroids in weight lifters. Eur Heart J 1998; 17: 1576-83
66. World Health Organization. Risks and Benefits of Androgen Therapy. Guidelines for the Use of Androgens in Men. Geneva: WHO, 1992: 5-6
67. Wemyss-Holden SA, Hamdy FC, Hastie KJ. Steroid abuse in athletes, prostatic enlargement and bladder outflow obstruction: is there a relationship? Br J Urol 1994; 74: 476-8
68. Holmang S, Marin P, Lindstedt G, Hedelin H. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate 1993; 23: 99-106
69. Jin B, Turner L, Walters WA, Handelsman DJ. Androgen or estrogen effects on human prostate. J Clin Endocrinol Metab 1996; 81: 4290-5
70. Negro-Vilar A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab 1999; 84: 3459-62
71. Roy AK, Tyagi RK, Song CS, et al. Androgen receptor: structural domains and functional dynamics after ligand-receptor interaction. Ann N Y Acad Sci 2001; 949: 44-57
72. Celotti F, Cesi PN. Anabolic-steroids: a review of their effects on the muscles, of their possible mechanisms of action and of their use in athletics. J Steroid Biochem Mol Biol 1992; 43: 469-77
73. Toth M, Zakar T. Relative binding affinities of testosterone, 19-nortestosterone and their 5-α-reduced derivatives to the androgen receptor and to other androgen-binding proteins: a suggested role of 5-α-reductive steroid-metabolism in the dissociation of myotropic and androgenic activities of 19-nortestosterone. J Steroid Biochem Mol Biol 1982; 17: 653-60
74. Potts GO, Arnold A, Beyler AL. Dissociation of the androgenic and other hormonal activities from the protein anabolic effects of steroids. In: Kochakian CD, ed. Handbook of Experimental Pharmacology, Vol. 43. Berlin: Springer-Verlag, 1976: 361-401
75. van der Vies J. Pharmacokinetics of anabolic steroids. Wien Med Wochenschr 1993; 143: 366-8
76. Miyamoto H, Yeh S, Lardy H, Messing E, Chang C. Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc Natl Acad Sci USA 1998; 95: 11083-8
77. Gower DB, Houghton E, Kicman AT. Anabolic steroids: metabolism, doping and detection in equestrian and human sports. In: Makin HLJ, Gower DB, Kirk DN, eds. Steroid Analysis. Glasgow: Blackie Academic & Professional, 1995: 468-526
78. Schänzer W, Donike M. Metabolism of anabolic steroids in man: synthesis and use of reference substances for identification of anabolic steroid metabolites. Anal Chim Acta 1993; 275: 23-48
79. Bowers LB. Metabolic pattern of mibolerone. In: Donike M, Geyer H, Gotzmann A, Mareck-Engelke U, eds. Recent Advances in Doping Analysis. Proceedings of the 13th Cologne Workshop on Dope Analysis. Koln: Sport und Buch Strauss, 1996: 81-2
80. Uralets VP, Gillette PA, DuVall B, Latven RK. Trenbolone: screening and confirmation. In: Donike M, Geyer H, Gotzmann A, Mareck-Engelke U, eds. Recent Advances in Doping Analysis. Proceedings of the 13th Cologne Workshop on Dope Analysis. Koln: Sport und Buch Strauss, 1996: 83-94
81. Masse R, Bi HG, Ayotte C, Du P, Gelinas H, Dugal R. Studies on anabolic steroids. V. Sequential reduction of methandienone and structurally related steroid A-ring substituents in humans: gas chromatographic-mass spectrometric study of the corresponding urinary metabolites. J Chromatogr 1991; 562: 323-40
82. Masse R, Bi HG, Ayotte C, Dugal R. Studies on anabolic steroids. II: Gas chromatographic/mass spectrometric characterization of oxandrolone urinary metabolites in man. Biomed Environ Mass Spectrom 1989; 18: 429-38
83. Masse R, Ayotte C, Bi HG, Dugal R. Studies on anabolic steroids. III. Detection and characterization of stanozolol urinary metabolites in humans by gas chromatography-mass spectrometry. J Chromatogr 1989; 497: 17-37
84. Durbeck HW, Buker I. Studies on anabolic steroids. The mass spectra of 17α-methyl-17β-hydroxy-1,4-androstadien-3-one (Dianabol) and its metabolites. Biomed Mass Spectrom 1980; 7: 437-45
85. Durbeck HW, Buker I, Scheulen B, Telin B. GC and capillary column GC/MS determination of synthetic anabolic steroids. II. 4-Chloro-methandienone (oral turinabol) and its metabolites. J Chromatogr Sci 1983; 21: 405-10
86. Durbeck HW, Buker I, Scheulen B, Telin B. Gas chromatographic and capillary column gas chromatographic-mass spectrometric determination of synthetic anabolic steroids. I. Methandienone and its metabolites. J Chromatogr 1978; 167: 117-24
87. Bi H, Masse R. Studies on anabolic steroids 12. Epimerization and degradation of anabolic 17β-sulfate-17α-rnethyl steroids in human: qualitative and quantitative GC/MS analysis. J Steroid Biochem Mol Biol 1992; 42: 533-46
88. Schanzer W, Geyer H, Donike M. Metabolism of metandienone in man: identification and synthesis of conjugated excreted urinary metabolites, determination of excretion rates and gas chromatographic-mass spectrometric identification of bishydroxylated metabolites. J Steroid Biochem Mol Biol 1991; 38: 441-64
89. Edlund PO, Bowers L, Henion J, Covey TR. Rapid-determination of methandrostenolone in equine urine by isotope-dilution liquid-chromatography tandem mass-spectrometry. J Chromatogr B 1989; 497: 49-57
90. Birch AJ. Hydroaromatic steroid hormones. Part 1. 19-Nortestosterone. J Am Chem Soc 1950; 44: 367-8
91. Engel LL, Alexander J, Wheeler M. Urinary metabolites of administered 19-nortestosterone. J Biol Chem 1958; 231: 159-64
92. Masse R, Laliberte C, Tremblay L, Dugal R. Gas chromatographic/mass spectrometric analysis of 19-nortestosterone urinary metabolites in man. Biomed Mass Spectrom 1985; 12: 115-21
93. Rongone E, Segaloff F. In vivo metabolism of δ-1,17-α-methyltestosterone. Steroids 1963; 1: 179-84
94. Schanzer W, Opfermann G, Donike M. Metabolism of stanozolol: identification and synthesis of urinary metabolites. J Steroid Biochem 1990; 36: 153-74
95. Clay KL, Watkins WD, Murphy RC. Metabolism of pyrazole. Structure elucidation of urinary metabolites. Drug Metab Dispos 1977; 5: 149-56
96. Ayotte C, Charlebois A, Lapointe S, Barriault D, Sylvestre M. Validity of urine samples; microbial degradation. In: Schanzer W, Geyer H, Gotzmann A, Mareck-Engelke U, eds. Recent Advances in Doping Analysis (4). Proceedings of the Manfred Donike Workshop, 14th Cologne Workshop on Dope Analysis, 17th to 22nd March 1996. Koln: Sport und Buch Strauss, 1997: 127-37
97. Bilton RF. Microbial production of testosterone [letter]. Lancet 1995; 345: 1186-7
98. Birchard K. Why doctors should worry about doping in sport. Lancet 1998; 352: 42
99. Honour JW. Testing for drug abuse. Lancet 1996; 348: 41-3
100. de la Torre R, de la Torre X, Alia C, Segura J, Baro T, Torres-Rodriguez JM. Changes in androgenic steroid profile due to urine contamination by microorganisms: a prospective study in the context of doping control. Anal Biochem 2001; 289: 116-23
101. Kicman AT, Fallon JK, Cowan DA, Walker C, Easmon S, Mackintosh D. Candida albicans can produce testosterone: impact on the T/E sports drug test. Clin Chem 2002; 10: 1799-801
102. Peng SH, Segura J, Farre M, de la Torre X. Oral testosterone administration detected by testosterone glucuronidation measured in blood spots dried on filter paper. Clin Chem 2000; 46: 515-22
103. Rivier L. Is there a place for hair analysis in doping controls? Forensic Sci Int 2000; 107: 309-23
104. Wennig R. Potential problems with the interpretation of hair analysis results. Forensic Sci Int 2000; 107: 5-12
105. Sachs H, Dressler U. Detection of THCCOOH in hair by MSD-NCI after HPLC clean-up. Forensic Sci Int 2000; 107: 239-47
106. Nakahara Y, Takahashi K, Kikura R. Hair analysis for drugs of abuse. X. Effect of physicochemical properties of drugs on the incorporation rates into hair. Biol Pharm Bull 1995; 18: 1223-7
107. Rollins DE, Wilkins DG, Krueger GG. Codeine disposition in human hair after single and multiple doses. Eur J Clin Pharmacol 1996; 50: 391-7
108. Henderson GL, Harkey MR, Zhou C, Jones RT, Jacob P 3rd. Incorporation of isotopically labeled cocaine and metabolites into human hair: 1. Dose-response relationships. J Anal Toxicol 1996; 20: 1-12
109. Kintz P, Cirimele V, Ludes B. Pharmacological criteria that can affect the detection of doping agents in hair. Forensic Sci Int 2000; 107: 325-34
110. Segura J, Pichini S, Peng SH, de la Torre X. Hair analysis and detectability of single dose administration of androgenic steroid esters. Forensic Sci Int 2000; 107: 347-59
111. Galliard Y, Vayssette F, Pepin G. Compared interest between hair analysis and urinalysis in doping controls. Results for amphetamines, corticosteroids and anabolic steroids in racing cyclists. Forensic Sci Int 2000; 107: 361-79
112. Cone EJ. Mechanisms of drug incorporation into hair. Ther Drug Monit 1996; 18: 438-43
113. Jurado C, Kintz P, Menendez M, Repetto M. Influence of the cosmetic treatment of hair on drug testing. Int J Legal Med 1997; 110: 159-63
114. Kidwell DA. Is hair testing culturally biased and why is this a concern in the US? Second European Meeting on Hair Analysis, Martigny, Switzerland, 14-16 June 1999
115. Vanluchene E, Eechaute W, Vandekerckhove D. Conversion of free 3β-hydroxy-5-ene-steroids by incubation with Helix pomatia. J Steroid Biochem 1982; 16: 701-3
116. Messeri G, Cugnetto G, Moneti G, Serio M. Helix pomatia induced conversion of some 3β-hydroxysteroids. J Steroid Biochem 1984; 20: 793-6
117. Houghton E, Grainger L, Durnasia MC, Teale P. application of gaschromatography-mass spectrometry to steroid analysis in equine sports: problems with enzyme hydrolysis. Org Mass Spectrom 1992; 27: 1061-70
118. Donike M, Zimmermann J. Preparation of trimethylsilyl, triethylsilyl and tert-butyldimethylsilyl enol ethers from ketosteroids for investigations by gas-chromatography and mass-spectrometry. J Chromatogr 1980; 202: 483-6
119. Opfermann G, Schanzer W. Trimethylsilylation: aspects for derivatisation. In: Schanzer W, Geyer H, Gotzmann A, Mareck-Engelke U, eds. Recent Advances in Doping Analysis (4). Proceedings of the 14th Cologne Workshop on Dope Analysis 17th to 22nd March 1996. Koln: Sport und Buch Strauss, 1997: 247-52
120. Masse R, Ayotte C, Dugal R. Studies on anabolic steroids. I. Integrated methodological approach to the gas chromatographic-mass spectrometric analysis of anabolic steroid metabolites in urine. J Chromatogr 1989; 489: 23-50
121. Ayotte C, Goudreault D, Charlebois A. Testing for natural and synthetic anabolic agents in human urine. J Chromatogr B 1996; 687: 3-25
122. Donike M, Geyer H, Gotzmann A, et al. Dope analysis. In: Bellotti P, Benzi G, Ljungqvist A, eds. International Athletic Foundation World Symposium on Doping in Sport: Official Proceedings, Florence, 10-12 May, 1987: International Athletic Foundation (IAF), 1988: 53-80
123. Bowers LD. Analytical advances in detection of performance-enhancing compounds. Clin Chem 1997; 43: 1299-304
124. Horning S, Donike M. High resolution GC/MS. In: Donike M, Geyer H, Gotzmann A, Mareck-Engelke U, Rauth S, eds. Recent Advances in Doping Analysis. Proceedings of the 11th Cologne Workshop on Dope Analysis 7th to 12th March 1993. Koln: Sport und Buch Strauss, 1994: 155-61
125. Mueller RK, Grosse J, Lang R, Thieme D. Chromatographic techniques: the basis of doping control. J Chromatogr B 1995; 674: 1-11
126. Kokkonen J, Leinonen A, Tuominen J, Seppala T. Comparison of sensitivity between gas chromatography-low-resolution mass spectrometry and gas chromatography-high-resolution mass spectrometry for determining metandienone metabolites in urine. J Chromatogr B 1999; 734: 179-89
127. Schanzer W, Delahaut P, Geyer H, Machnik M, Horning S. Long-term detection and identification of metandienone and stanozolol abuse in athletes by gas chromatography - high-resolution mass spectrometry. J Chromatogr B 1996; 687: 93-108
128. Horning S, Schanzer W. Steroid screening using GC/HRMS. In: Schanzer W, Geyer H, Gotzmann A, Mareck-Engelke U, eds. Recent Advances in Doping Analysis (4). Proceedings of the 14th Cologne Workshop on Dope Analysis 17th to 22nd March 1993. Koln: Sport und Buch Strauss, 1997: 261-74
129. Bowers LD, Borts DJ. Evaluation of selected-ion storage ion-trap mass spectrometry for detecting urinary anabolic agents. Clin Chem 1997; 43: 1033-9
130. Bowers LD, Borts DJ. Separation and confirmation of anabolic steroids with quadrupole ion trap tandem mass spectrometry. J Chromatogr B 1996; 687: 69-78
131. Kicman AT, Cowan DA, Myhre L, Nilsson S, Tomten S, Oftebro H. Effect on sports drug tests of ingesting meat from steroid (methenolone)-treated livestock. Clin Chem 1994; 40: 2084-7
132. Goudreault D, Masse R. Studies on anabolic steroids 4. Identification of new urinary metabolites of methenolone acetate (Primobolan) in human by gas chromatography/mass spectrometry. J Steroid Biochem Mol Biol 1990; 37: 137-54
133. Schanzer W, Opfermann G, Donike M. 17-Epimerization of 17α-methyl anabolic steroids in humans: metabolism and synthesis of 17α-hydroxy-17β-methyl steroids. Steroids 1992; 57: 537-50
134. Expert Committee on Nandrolone. Nandrolone Review. Report to UK Sport, January 2000. Available from UK Sport, London
135. Thevis M, Opfermann G, Schmickler H, Schanzer W. Mass spectrometry of steroid glucuronide conjugates. I. Electron impact fragmentation of 5α/5β-androstan-3α-ol-17-one glucuronides, fα-estran-3α-ol-17-one glucuronide and deuterium-labelled analogues. J Mass Spectrom 2001; 36: 159-68
136. Thevis M, Opfermann G, Schmickler H, Schanzer W. Mass spectrometry of steroid glucuronide conjugates. II: Electron impact fragmentation of 3-keto-4-en- and 3-keto-5alpha-steroid-17-O-beta glucuronides and 5alpha-steroid-3alpha,17beta-diol 3- and 17-glucuronides. J Mass Spectrom 2001; 36: 998-1012
137. Kuuranne T, Vahermo M, Leinonen A, Kostiainen R. Electrospray and atmospheric pressure chemical ionization tandem mass spectrometric behavior of eight anabolic steroid glucuronides. J Am Soc Mass Spectrom 2000; 11: 722-30
138. Choi MH, Kim KR, Chung BC. Simultaneous determination of urinary androgen glucuronides by high temperature gas chromatography-mass spectrometry with selected ion monitoring. Steroids 2000; 65: 54-9
139. Borts DJ, Bowers LD. Direct measurement of urinary testosterone and epitestosterone conjugates using high-performance liquid chromatography/tandem mass spectrometry. J Mass Spectrom 2000; 35: 50-61
140. Bowers LD, Sanaullah. Direct measurement of steroid sulfate and glucuronide conjugates with high-performance liquid chromatography mass spectrometry. J Chromatogr B 1996; 687: 61-8
141. Kruskemper HL. Creatine Metabolism. Anabolic Steroids. New York: Academic Press, 1968: 58-60
142. Townsley JD, Brodie HJ. Studies on the mechanism of estrogen biosynthesis. IV. Ovarian metabolism of estr-4-ene-3,17-dione. Biochim Biophys Acta 1967; 144: 440-5
143. Farnsworth WE. Metabolism of 19-nortestosterone by human prostate. Steroids 1966; 8: 825-44
144. Cole PA, Robinson CH. Mechanism and inhibition of cytochrome P-450 aromatase. J Med Chem 1990; 33: 2933-42
145. Beusen DD, Carrell HL, Covey DF. Metabolism of 19-methylsubstituted steroids by human placental aromatase. Biochemistry 1987; 26: 7833-41
146. Silberzahn P, Dehennin L, Zwain I, Reiffsteck A. Gas chromatography-mass spectrometry of androgens in equine ovarian follicles at ultrastructurally defined stages of development. Identification of 19-nortestosterone in follicular fluid. Endocrinology 1985; 117: 2176-81
147. Reznik Y, Herrou M, Dehennin L, Lemaire M, Leymarie P. Rising plasma levels of 19-nortestosterone throughout pregnancy: determination by radioimmunoassay and validation by gas chromatography-mass spectrometry. J Clin Endocrinol Metab 1987; 64: 1086-8
148. de Boer D, Bensink SN, Borggreve AR, VanOoijen RD, Maes RAA. Profiling 19-norsteroids III: GC/MS/MS analysis of 19-norsteroids during pregnancy. In: Donike M, Geyer H, Gotzmann A, Mareck-Engelke U, Rauth S, eds. 10th Cologne Workshop on Dope Analysis: Proceedings, 7th to 12th June 1992. Koln: Sport und Buch Strauss, 1993: 121-2
149. Mareck-Engelke U, Geyer H, Schanzer W. The interpretation of female steroid profiles. In: Schanzer W, Geyer H, Gotzmann A, Mareck-Engelke U, eds. Recent Advances in Doping Analysis (5). Proceedings of the Manfred Donike Workshop: 15th Cologne Workshop on Dope Analysis 23rd to 28th February 1997. Koln: Sport und Buch Strauss, 1998: 51-70
150. Van Eenoo P, Delbecke FT, de Jong FH, De Backer P. Urinary metabolites of endogenous nandrolone in women: a case study. In: Schanzer W, Geyer H, Gotzmann A, Mareck-Engelke U, eds. Recent Advances in Doping Analysis (6). Proceedings of the Manfred Donike Workshop: 16th Cologne Workshop on Dope Analysis 15th to 20th March 1998. Koln: Sport und Buch Strauss, 1999: 105-17
151. Mareck-Engelke U, Schultze G, Geyer H, Schanzer W. The appearance of urinary 19-norandrosterone during pregnancy. Eur J Sports Sci 2002; 2: 1-7
152. Dehennin L, Bonnaire Y, Plou P. Urinary excretion of 19-norandrosterone of endogenous origin in man: quantitative analysis by gas chromatography mass spectrometry. J Chromatogr B 1999; 721: 301-7
153. Le Bizec B, Monteau F, Gaudin I, Andre F. Evidence for the presence of endogenous 19-norandrosterone in human urine. J Chromatogr B 1999; 723: 157-72
154. Ciardi M, Ciccoli R, Barbarulo MV, Nicoletti R. Presence of norandrosterone in 'normal' urine samples. In: Schanzer W, Geyer H, Gotzmann A, Mareck-Engelke U, eds. Recent Advances in Doping Analysis (6). Proceedings of the Manfred Donike Workshop: 16th Cologne Workshop on Dope Analysis 15th to 20th March 1998. Koln: Sport und Buch Strauss, 1999: 97-104
155. Reznik Y, Dehennin L, Coffin C, Mahoudeau J, Leymarie P. Urinary nandrolone metabolites of endogenous origin in man: a confirmation by output regulation under human chorionic gonadotropin stimulation. J Clin Endocrinol Metab 2001; 86: 146-50
156. Saugy M, Robinson N, Cardis C, et al. Nandrolone metabolites in football players: utility for in and out of competition testing. In: Schanzer W, Geyer H, Gotzmann A, Mareck-Engelke U, eds. Recent Advances in Doping Analysis (7). Proceedings of the Manfred Donike Workshop. Köln: Sport und Buch Strauss, 1999
157. Robinson N, Taroni F, Saugy M, Ayotte C, Mangin P, Dvorak J. Detection of nandrolone metabolites in urine after a football game in professional and amateur players: a Bayesian comparison. Forensic Sci Int 2001; 122: 130-5
158. Le Bizec B, Bryand F, Gaudin I, Monteau F, Poulain F, Andre F. Endogenous nandrolone metaborites in human urine. Two-year monitoring of male professional soccer players. J Anal Toxicol 2002; 26: 43-7
159. Schmitt N, Flament MM, Goubault C, Legros P, Grenier-Loustalot MF, Denjean A. Nandrolone excretion is not increased by exhaustive exercise in trained athletes. Med Sci Sports Exerc 2002; 34: 1436-9
160. Le Bizec B, Bryand F, Gaudin I, Monteau F, Poulain F, Andre F. Endogenous nandrolone metabolites in human urine: preliminary results to discriminate between endogenous and exogenous origin. Steroids 2002; 67: 105-10
161. Mathurin JC, Herrou V, Bourgogne E, Pascaud L, de Ceaurriz J. Gas chromatography-combustion-isotope ratio mass spectrometry analysis of 19-norsteroids: application to the detection of a nandrolone metabolite in urine. J Chromatogr B 2001; 759: 267-75
162. Desroches MC, Mathurin JC, Richard Y, Delahaut P, de Ceaurriz J. Urinary 19-norandrosterone purification by immunoaffinity chromatography: application to gas chromatography/combustion/ isotope ratio mass spectrometric analysis. Rapid Commun Mass Spectrom 2002; 16: 370-4
163. Le Bizec B, Gaudin I, Monteau F, et al. Consequence of boar edible tissue consumption on urinary profiles of nandrolone metabolites. I. Mass spectrometric detection and quantification of 19-norandrosterone and 19-noretiocholanolone in human urine. Rapid Commun Mass Spectrom 2000; 14: 1058-65
164. Machnik M, Scrader Y, Schanzer W. Plasma levels of 19-norsteroids after oral and buccal administration of norandrostenedione. In: Schanzer W, Geyer H, Gotzmann A, Mareck-Engelke U, eds. Recent Advances in Doping Analysis (9). Proceedings of the Manfred Donike Workshop: 19th Cologne Workshop on Dope Analysis, 18th to 23rd March 2001. Koln: Sport und Buch Strauss, 2001: 125-31
165. Belkien L, Schurmeyer T, Hano R, Gunnarsson PO, Nieschlag E. Pharmacokinetics of 19-nortestosterone esters in normal men. J Steroid Biochem Mol Biol 1985; 22: 623-9
166. Wijnand HP, Bosch AMG, Donker CW. Pharmacokinetic parameters of nandrolone (19-nortestosterone) after intramuscular administration of nandrolone decanoate (deca-durabolin) to healthy-volunteers. Acta Endocrinol 1985; 110: 19-30
167. Minto CF, Howe C, Wishart S, Conway AJ, Handelsman DJ. Pharmacokinetics and pharmacodynamics of nandrolone esters in oil vehicle: effects of ester, injection site and injection volume. J Pharmacol Exp Ther 1997; 281: 93-102
168. Cowan DA, Kicman AT. Doping in sport: misuse, analytical tests, and legal aspects [editorial]. Clin Chem 1997; 43: 1110-3
169. Donike M, Barwald KR, Klostermann K, Schanzer W, Zimmermann J. Nachweis von exogenem Testosteron [Detection of endogenous testosterone]. In: Heck H, Hollmann W, Liesen H, et al., eds. Sport: Leistung und Gesundheit, Kongressbd. Dtsch. Sportärztekongress. Köln: Deutscher Ärtze-Verlag, 1983: 293-8
170. Dehennin L. Secretion by the human testis of epitestosterone, with its sulfoconjugate and precursor androgen 5-androstene-3beta,17alpha-diol. J Steroid Biochem Mol Biol 1993; 44: 171-7
171. Kicman AT, Coutts SB, Cowan DA, et al. Adrenal and gonadal contributions to urinary excretion and plasma concentration of epitestosterone in men: effect of adrenal stimulation and implications for detection of testosterone abuse. Clin Endocrinol (Oxf) 1999; 50: 661-8
172. Dehennin L, Matsumoto AM. Long-term administration of testosterone enanthate to normal men: alterations of the urinary profile of androgen metabolites potentially useful for detection of testosterone misuse in sport. J Steroid Biochem Mol Biol 1993; 44: 179-89
173. Palonek E, Gottlieb C, Garle M, Bjorkhem I, Carlstrom K. Serum and urinary markers of exogenous testosterone administration. J Steroid Biochem Mol Biol 1995; 55: 121-7
174. Anderson RA, Wallace AM, Kicman AT, Wu FC. Comparison between testosterone oenanthate-induced azoospermia and oligozoospermia in a male contraceptive study. IV. Suppression of endogenous testicular and adrenal androgens. Hum Reprod 1997; 12: 1657-62
175. Dehennin L, Jondet M, Scholler R. Androgen and 19-norsteroid profiles
176. Oftebro H. Evaluating an abnormal urinary steroid profile. Lancet 1992; 339: 941-2
177. Kicman AT, Oftebro H, Walker C, Norman N, Cowan DA. Potential use of ketoconazole in a dynamic endocrine test to differentiate between biological outliers and testosterone use by athletes. Clin Chem 1993; 39: 1798-803
178. Oftebro H, Jensen J, Mowinckel P, Norli HR. Establishing a ketoconazole suppression test for verifying testosterone administration in the doping control of athletes. J Clin Endocrinol Metab 1994; 78: 973-7
179. Raynaud E, Audran M, Pages JC, et al. Urinary-excretion of testosterone and epitestosterone glucuronides in preadolescents and adolescents. Pathol Biol 1993; 41: 159-63
180. Raynaud E, Audran M, Pages JC, et al. Determination of urinary testosterone and epitestosterone during pubertal development: a cross-sectional study in 141 normal male subjects. Clin Endocrinol 1993; 38: 353-9
181. Garle M, Ocka R, Palonek E, Bjorkhem I. Increased urinary testosterone epitestosterone ratios found in Swedish athletes in connection with a national control program: evaluation of 28 cases. J Chromatogr B 1996; 687: 55-9
182. Donike M, Rauth S, Mareck-Engelke U, Geyer H, Nitschke R. Evaluation of longitudinal studies, the determination of subject based reference ranges of the testosterone/epitestosterone ratio. In: Donike M, Geyer H, Gotzmann A, Mareck-Engelke U, Rauth S, eds. Recent Advances in Doping Analysis. Proceedings of the 11th Cologne Workshop on Dope Analysis 7th to 12th March 1993. Koln: Sport und Buch Strauss, 1994: 33-9
183. Donike M, Mareck-Engelke U, Rauth S. Statistical evaluation of longitudinal studies, part 2: the usefulness of subject based reference ranges in steroid profiling. In: Donike M, Geyer H, Gotzmann A, Mareck-Engelke U, eds. Recent Advances in Doping Analysis. Proceedings of the 12th Cologne Workshop on Dope Analysis 10-15th April 1994. Koln: Sport und Buch Strauss, 1995: 157-65
184. Harris EK. Some theory of reference values. I. Stratified (categorized) normal ranges and a method for following an individual's clinical laboratory values. Clin Chem 1975; 21: 1457-64
185. Harris EK, Cooil BK, Shakarji G, Williams GZ. On the use of statistical models of within-person variation in long-term studies of healthy individuals. Clin Chem 1980; 26: 383-91
186. Catlin DH, Hatton CK, Starcevic SH. Issues in detecting abuse of xenobiotic anabolic steroids and testosterone by analysis of athletes' urine. Clin Chem 1997; 43: 1280-8
187. Palonek E, Gottlieb C, Garle M, Bjorkhem I, Carlstrom K. Serum and urinary markers of exogenous testosterone administration. J Steroid Biochem Mol Biol 1995; 55: 121-7
188. Carlstrom K, Palonek E, Garle M, Oftebro H, Stanghelle J, Bjorkhem I. Detection of testosterone administration by increased ratio between serum concentrations of testosterone and 17alpha-hydroxyprogesterone. Clin Chem 1992; 38: 779-84
189. Dehennin L. On the origin of physiologically high ratios of urinary testosterone to epitestosterone: consequences for reliable detection of testosterone administration by male athletes. J Endocrinol 1994; 142: 353-60
190. Perry PJ, MacIndoe JH, Yates WR, Scott SD, Holman TL. Detection of anabolic steroid administration: ratio of urinary testosterone to epitestosterone vs the ratio of urinary testosterone to luteinizing hormone. Clin Chem 1997; 43: 731-5
191. Yap BK, Kazlauskas R, Elghazi K, Johnston GAR, Weatherby RP. Profiling of urinary testosterone and luteinizing hormone in exercise-stressed male athletes, using gas chromatography mass spectrometry and enzyme immunoassay techniques. J Chromatogr B 1996; 687: 117-25
192. Southan GJ, Brooks RV, Cowan DA, Kicman AT, Unnadkat N, Walker CJ. Possible indices for the detection of the administration of dihydrotestosterone to athletes. J Steroid Biochem Mol Biol 1992; 42: 87-94
193. Kicman AT, Coutts SB, Walker CJ, Cowan DA. Proposed confirmatory procedure for detecting 5alpha-dihydrotestosterone doping in male athletes. Clin Chem 1995; 41: 1617-27
194. Donike M, Ueki M, Kuroda Y, et al. Detection of dihydrotestosterone (DHT) doping: alterations in the steroid profile and reference ranges for DHT and its 5alpha-metabolites [editorial]. J Sports Med Phys Fitness 1995; 35: 235-50
195. Coutts SB, Kicman AT, Hurst DT, Cowan DA. Intramuscular administration of 5alpha-dihydrotestosterone heptanoate: changes in urinary hormone profile. Clin Chem 1997; 43: 2091-8
196. Dehennin L, Ferry M, Lafarge P, Peres G, Lafarge JP. Oral administration of dehydroepiandrosterone to healthy men: alteration of the urinary androgen profile and consequences for the detection of abuse in sport by gas chromatography-mass spectrometry. Steroids 1998; 63: 80-7
197. Bosy TZ, Moore KA, Poklis A. The effect of oral dehydroepiandrosterone (DHEA) on the urine testosterone/epitestosterone (T/E) ratio in human male volunteers. J Anal Toxicol 1998; 22: 455-9
198. Bowers LD. Oral dehydroepiandrosterone supplementation can increase the testosterone/epitestosterone ratio. Clin Chem 1999; 45: 295-7
199. Levesque J-F, Ayotte C. Criteria for the detection of androstenedione oral administration. In: Schanzer W, Geyer H, Gotzmann A, Mareck-Engelke U, eds. Recent Advances in Doping Analysis (7). Proceedings of the Manfred Donike Workshop: 17th Cologne Workshop on Dope Analysis, 14th to 19th March 1999. Koln: Sport und Buch Strauss, 1999
200. Goudreault D, Bherer P, Levesque JF, Pourier D, Ayotte C. Androstenedione metabolism: end of the story. In: Schanzer W, Geyer H, Gotzmann A, Mareck-Engelke U, eds. Recent Advances in Doping Analysis (9). Proceedings of the Manfred Donike Workshop: 19th Cologne Workshop on Dope Analysis, 18th to 23rd March 2001. Koln: Sport und Buch Strauss, 2001: 73-83
201. Van Eenoo P, Delbeke FT, Desmet N, De Backer P. Excretion studies with 4-androstene-3,17-dione. In: Schanzer W, Geyer H, Gotzmann A, Mareck-Engelke U, eds. Recent Advances in Doping Analysis (6). Proceedings of the Manfred Donike Workshop: 16th Cologne Workshop on Dope Analysis 15th to 20th March 1998. Koln: Sport und Buch Strauss, 1999: 171-80
202. Laidler P, Cowan DA, Hider RC, Kicman AT. New decision limits and quality-control material for detecting human chorionic gonadotropin misuse in sports. Clin Chem 1994; 40: 1306-11
203. Becchi M, Aguilera R, Farizon Y, Flament MM, Casabianca H, James P. Gas chromatography/combustion/isotope-ratio mass spectrometry analysis of urinary steroids to detect misuse of testosterone in sport. Rapid Commun Mass Spectrom 1994; 8: 304-8
204. Aguilera R, Becchi M, Grenot C, Casabianca H, Hatton CK. Detection of testosterone misuse: comparison of two chromatographic sample preparation methods for gas chromatographic-combustion/isotope ratio mass spectrometric analysis. J Chromatogr B 1996; 687: 43-53
205. Aguilera R, Becchi M, Casabianca H, et al. Improved method of detection of testosterone abuse by gas chromatography/ combustion/isotope ratio mass spectrometry analysis of urinary steroids. J Mass Spectrom 1996; 31: 169-76
206. Aguilera R, Catlin DH, Becchi M, et al. Screening urine for exogenous testosterone by isotope ratio mass spectrometric analysis of one pregnanediol and two androstanediols. J Chromatogr B 1999; 727: 95-105
207. Shackleton CH, Phillips A, Chang T, Li Y. Confirming testosterone administration by isotope ratio mass spectrometric analysis of urinary androstanediols. Steroids 1997; 62: 379-87
208. Horning S, Geyer H, Machnik M, Schanzer W, Hilkert A, Oesselmann J. Detection of exogenous testosterone by 13C/12C analysis. In: Schanzer W, Geyer H, Gotzmann A, Mareck-Engelke U, eds. Recent Advances in Doping Analysis. Proceedings of the 14th Cologne Workshop on Dope Analysis. Koln: Sport und Buch Strauss, 1997: 275-83
209. Cowan DA, Kicman AT, Walker CJ, Wheeler MJ. Effect of administration of human chorionic gonadotrophin on criteria used to assess testosterone administration in athletes. J Endocrinol 1991; 131: 147-54
210. de Boer D, de Jong EG, van Rossum JM, Maes RA. Doping control of testosterone and human chorionic gonadotrophin: a case study [published erratum appears in Int J Sports Med 1991; 12: 430]. Int J Sports Med 1991; 12: 46-51
211. Kicman AT, Brooks RV, Cowan DA. Human chorionic gonadotrophin and sport. Br J Sports Med 1991; 25: 73-80
212. Brooks RV, Collyer SP, Kicman AT, Southan GJ, Wheeler MA. HCG doping in sport and methods for its detection. In: Bellotti P, Benzi G, Ljungqvist A, eds. IInd International Athletic Foundation World Symposium on Doping in Sport. Official Proceedings, Monte Carlo, 5-7 June 1989: International Athletic Foundation (IAF), 1990: 37-45
213. Stenman UH, Unkila-Kallio L, Korhonen J, Alfthan H. Immunoprocedures for detecting human chorionic gonadotropin: clinical aspects and doping control. Clin Chem 1997; 43: 1293-8
214. Laidler P, Cowan DA, Hider RC, Keane A, Kicman AT. Tryptic mapping of human chorionic gonadotropin by matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom 1995; 9: 1021-6
215. Liu CL, Bowers LB. Immunoaffinity trapping of urinary human chorionic gonadotropin and its high-performance liquid chromatographic-mass spectrometric confirmation. J Chromatogr B 1996; 687: 213-20
216. Kicman AT, Brooks RV, Collyer SC, et al. Criteria to indicate testosterone administration. Br J Sports Med 1990; 24: 253-64
217. Aguilera R, Hatton CK, Catlin DH. Detection of epitestosterone doping by isotope ratio mass spectrometry. Clin Chem 2002; 48: 629-36
218. Geyer H, Schanzer W, Donike M. Probenecid as masking agent in dope control: inhibition of the urinary excretion of steroid glucuronides. In: Donike M, Geyer H, Gotzmann A, MareckEngelke U, Rauth S, eds. 10th Cologne Workshop on Dope Analysis: Proceedings, 7th to 12th June 1992. Koln: Sport und Buch Strauss, 1993: 141-51
219. Randall VA. Role of 5alpha-reductase in health and disease. Baillieres Clin Endocrinol Metab 1994; 8: 405-31
220. Bull HG, GarciaCalvo M, Andersson S, et al. Mechanism-based inhibition of human steroid 5alpha-reductase by finasteride: enzyme-catalyzed formation of NADP-dihydrofinasteride, a potent bisubstrate analog inhibitor. J Am Chem Soc 1996; 118: 2359-65
221. Geyer H, Nolteernsting E, Schanzer W. Finasteride: a substance for manipulation in dope control? In: Schanzer W, Geyer H, Gotzmann A, Mareck-Engelke U, eds. Recent Advances in Doping Analysis (7). Proceedings of the Manfred Donike Workshop: 17th Cologne Workshop on Dope Analysis, 14th to 19th March 1999. Koln: Sport und Buch Strauss, 1999: 71-80
222. Carlin JR, Hoglund P, Eriksson LO, et al. Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans. Drug Metab Dispos 1992; 20: 148-55